ER Niacin/Laropiprant Impact on Cardiovascular Markers and Atheroprogression in HIV-infected Individuals on cART
Phase of Trial: Phase IV
Latest Information Update: 14 Mar 2013
At a glance
- Drugs Niacin/laropiprant (Primary)
- Indications Ischaemic heart disorders
- Focus Biomarker; Pharmacodynamics
- Acronyms NILACH
- 07 Jun 2017 Biomarkers information updated
- 14 Mar 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 14 Mar 2013 Additional lead trial centres deleted as reported by ClinicalTrials.gov record.